Parkman Healthcare Partners’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Parkman Healthcare Partners’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-51,311	Closed	-$8.68M	–	112
2023 Q3	$8.68M	Buy	51,311 +2,078	+4%	+$391K	1.59%	17
2023 Q2	$10.7M	Buy	49,233 +9,926	+25%	+$2.13M	1.85%	18
2023 Q1	$7.14M	Buy	39,307 +20,407	+108%	+$3.9M	1.55%	26
2022 Q4	$3.71M	Buy	18,900 +6,900	+58%	+$1.48M	0.99%	41
2022 Q3	$2.7M	Buy	+12,000	New	+$2.43M	0.77%	50

Other funds holding KRTX

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Parkman Healthcare Partners's KRTX Position: Q4 2023 in Review

Parkman Healthcare Partners sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 51,311 shares — an estimated $8.68M sold.

Parkman Healthcare Partners first reported a position in KRTX in Q3 2022 and held it in 5 quarters. The position peaked at $10.7M in Q2 2023. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

Parkman Healthcare Partners reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Parkman Healthcare Partners sold 51,311 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $8.68M.
Parkman Healthcare Partners first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
Parkman Healthcare Partners's Karuna Therapeutics, Inc. Common Stock position peaked at $10.7M in Q2 2023.
328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.